Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Kidney (renal cell) cancer
Stage/Subtype:  recurrent renal cell cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 52 for your search:
Start Over
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Stereotactic Radiosurgery in Treating Patients With Kidney Tumors Who are Poor Candidates for Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 12806, NCI-2010-01064, NCT00458484
Genetically Modified T Cells, Aldesleukin, and Combination Chemotherapy in Treating Patients with Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0013, NCI-2013-01468, 1004-1036, 110013, 344344, P10648, RD-10-IV-02, NCT01218867
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
Everolimus and Hydroxychloroquine in Treating Patients With Previously Treated Kidney Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 07811, NCI-2012-00170, NCT01510119
Panobinostat and Everolimus in Treating Patients with Metastatic or Unresectable Renal Cell Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 146308, NCI-2009-01599, NCT01037257, NCT01582009
A Phase 1/2 Study to Evaluate MEDI4736
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CD-ON-MEDI4736-1108, NCI-2012-02062, NCT01693562
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-04, NCI-2015-00740, NCT02386111
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed By Donor Bone Marrow Transplant in Treating Patients With Hematologic Malignancy or Kidney Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Pentostatin and Cyclophosphamide Followed by Donor Stem Cell Transplant and Donor Lymphocyte Infusions in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 08-C-0088, NCI-2009-00299, CDR0000648215, NCT00641485, 8242, NCT00923845
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Sunitinib Malate with or without Gemcitabine Hydrochloride in Treating Patients with Advanced Kidney Cancer That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E1808, NCI-2011-02055, CDR0000681614, ECOG-E1808, NCT01164228
Tumor Infiltrating Lymphocytes and Aldesleukin after Chemotherapy in Treating Patients with Metastatic Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0166, NCI-2013-01461, 100166, P09567, NCT01174121
Everolimus and Bevacizumab in Treating Patients with Advanced Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-226, NCI-2011-01944, NCT01399918
Trebananib with or without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients with Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-122, NCI-2012-01289, CDR0000738785, 9048, NCT01664182
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1152, NCI-2012-02027, Mod11-003340-15, Mod11-003340-20, NCT01767636
C-met Inhibitor INCB028060 in Treating Patients with Papillary Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0037, NCI-2014-02464, 09-25-0099, 140037, 340263, P131324, NCT02019693
Dose-escalation Study of Oral CX-4945
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Recombinant Interleukin-15 in Treating Patients with Metastatic Melanoma or Kidney Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: 10-C-0021, NCI-2015-00085, 100021, 10-C-0021 G, 9850, NCT01021059
Pazopanib Hydrochloride and Everolimus in Treating Patients with Advanced Solid Tumors or Previously Treated Advanced Urothelial Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-166, NCI-2011-00034, NCT01184326
Everolimus and Lenalidomide in Treating Patients with Advanced Recurrent Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WCI-1717, NCI-2011-03388, CRAD001LUS141T, IRB00031088, RV-ST-PI-0558, WCI 1717-09, NCT01218555
A Study of LY2801653 in Advanced Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13008, NCI-2013-00662, I3O-MC-JSBA, NCT01285037
Start Over